Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Golden Lily Biotechnology, also known as Jinbaihe Biotechnology, is a Beijing-based life sciences company specializing in the development and manufacturing of recombinant proteins and diagnostic reagents. The company is a pioneer in the production of recombinant human collagen (rhCollagen), which is utilized extensively in medical aesthetics, regenerative medicine, and advanced skincare products. Their proprietary technology platform allows for the large-scale synthesis of high-purity proteins that exhibit high biological activity and low immunogenicity. Beyond its collagen portfolio, Golden Lily provides a diverse range of monoclonal antibodies and enzymes for clinical diagnostics and academic research. The company serves as a key raw material supplier for the global pharmaceutical and cosmetic industries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Golden Lily Biotechnology.